CVRx Inc (NAS:CVRX)
$ 8.01 0.29 (3.76%) Market Cap: 172.98 Mil Enterprise Value: 117.20 Mil PE Ratio: 0 PB Ratio: 2.61 GF Score: 33/100

CVRx Inc To Discuss Preliminary Results of the BeAT-HF Post-Market Clinical Trial Call Transcript

Mar 21, 2023 / 08:30PM GMT
Release Date Price: $9.47 (-3.66%)
Operator

Greetings, and welcome to CVRx shares preliminary results of the BeAT-HF post-market clinical trials. (Operator Instructions)

As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Nadim Yared, President and Chief Executive Officer. Thank you. You may begin.

Nadim Yared
CVRx, Inc. - CEO, President & Director

Good afternoon, and thank you for joining us today for this important update. I am excited to share with you the preliminary top line results of the post-market phase of our BeAT-HF trial, as presented at the Technology and Heart Failure Therapeutics Conference or THT in Boston today by Dr. Michael Zile, Chair of the Executive Steering Committee of the trial.

Before we go further, I need to state that the remarks today will contain forward-looking statements including statements about expected product developments, regulatory matters and business impacts. The statements are based on plans and expectations as of today, which may change over time.

In addition, actual results could

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot